FDA reschedules NeOnc Technologies' end-of-Phase 1 meeting on NEO212
NTHI•The FDA rescheduled NeOnc's end-of-Phase 1 meeting on NEO212 to Nov. 23, 2026, from Nov. 17. The company plans to seek feedback on Phase 2 trial plans and potential regulatory pathways for the oral CNS cancer treatment.
1. Meeting rescheduled
NeOnc's FDA end-of-Phase 1 meeting on NEO212 was rescheduled to Nov. 23, 2026, from Nov. 17, 2026. The company will seek feedback on Phase 2 trial plans and potential regulatory pathways for the oral CNS cancer treatment.




